Karyopharm grabs $48M round for pipeline work

Natick, MA-based Karyopharm Therapeutics has banked $48.2 million in Series B cash. The funds will be used to advance its pipeline of selective inhibitors of nuclear export (SINE) drug candidates for hematologic and solid tumors. An unnamed private investor joined additional investors and Delphi Ventures in coming up with the money. "This significant capital infusion will allow us to advance our lead drug candidate KPT-330 (currently in Phase I studies) in two oncology indications through full clinical development," stated Michael Kauffman, the CEO of Karyopharm. Release

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.